NEW YORK, NY / ACCESSWIRE / September 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

AHCO Shareholders Click Here: https://www.zlk.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=19530&wire=1
ITRM Shareholders Click Here: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19530&wire=1
LIVE Shareholders Click Here: https://www.zlk.com/pslra-1/live-ventures-incorporated-loss-submission-form?prid=19530&wire=1

* ADDITIONAL INFORMATION BELOW *

AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. (NASDAQ:AHCO)

AHCO Lawsuit on behalf of: investors who purchased November 11, 2019 - July 16, 2021
Lead Plaintiff Deadline : September 27, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/adapthealth-corp-f-k-a-dfb-healthcare-acquisitions-corp-loss-submission-form?prid=19530&wire=1

According to the filed complaint, during the class period, AdaptHealth Corp. f/k/a DFB Healthcare Acquisitions Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) AdaptHealth had misrepresented its organic growth trajectory by retroactively inflating past organic growth numbers without disclosing the changes, in violation of Securities and Exchange Commission regulations; (ii) accordingly, the Company had materially overstated its financial prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Iterum Therapeutics Plc (NASDAQ:ITRM)

ITRM Lawsuit on behalf of: investors who purchased November 30, 2020 - July 23, 2021
Lead Plaintiff Deadline : October 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19530&wire=1

According to the filed complaint, during the class period, Iterum Therapeutics Plc made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Live Ventures Incorporated (NASDAQ:LIVE)

LIVE Lawsuit on behalf of: investors who purchased December 28, 2016 - August 3, 2021
Lead Plaintiff Deadline : October 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/live-ventures-incorporated-loss-submission-form?prid=19530&wire=1

According to the filed complaint, during the class period, Live Ventures Incorporated made materially false and/or misleading statements and/or failed to disclose that: 1) Live's earnings per share for FY 2016 was actually only $6.33 per share; (2) the Company used an artificially low share count to boost the earnings per share by 40%; (3) Live had overstated pretax income for fiscal 2016 by 20% by including $915,500 of "other income" related to certain amendments that were not negotiated until after the close of the fiscal year; (4) Live's acquisition of ApplianceSmart did not close during first quarter 2017; (5) using December 30, 2017 as the "acquisition date" and recognizing income therefrom did not conform to generally accepted accounting principles; (6) by falsely stating that the acquisition closed during the quarter, Live recognized bargain purchase gain, which enabled the Company to report positive net income in what would otherwise have been an unprofitable quarter; (7) between fiscal 2016 and fiscal 2018, Live's CEO received approximately 94% more in compensation than was disclosed to investors; and (8) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP